Understanding and Accurately Predicting Low Clearance Compounds with Advanced in vitro Models
Capabilities
Unlock Accurate Predictions for Low Clearance Compounds
Advanced in vitro systems are important for building confidence throughout the drug development process. In addition, understanding low intrinsic clearance (low‑turnover) compounds and gaining clear insight into their metabolism is especially important. These insights support better PK predictions, dose selection, and DDI assessment.
At Pharmaron, we provide industry‑leading, validated in vitro low clearance studies designed to overcome these challenges and deliver reliable, human‑relevant and regulatory‑aligned data.
Why Low Clearance Studies Matter
Traditional short‑term hepatocyte assays often struggle to identify slow metabolic pathways, leading to underestimated clearance. This may result in less accurate IVIVE predictions, suboptimal dose selection and delay the identification of problems until later in the development process. Our validated low‑clearance in vitro models tackle these issues by generating robust, human‑relevant data to support confident project decisions.
Low clearance compounds bring special challenges throughout discovery and development:
- Under‑prediction of clearance when using traditional hepatocyte assays
- Poor IVIVE translation, leading to less reliable PBPK modeling
- Missed or underestimated metabolites that may contribute to safety or efficacy issues
- Inaccurate dose selection and risk of drug accumulation
Pharmaron’s advanced long‑term metabolic systems ensure you capture the full metabolic picture, meaning improving prediction accuracy and de‑risking for your development pipeline.
Pharmaron’s In Vitro Low Clearance Toolkit
Our low-turnover models provide improved sensitivity, long‑term metabolic activity, and validated IVIVE performance, enabling accurate characterization of even the most challenging low‑turnover drugs.
Suspension and Plated Hepatocyte Models:
- Extended incubation to capture slow metabolism
- Sensitive intrinsic clearance quantification
- PBPK‑ready data for human PK prediction
- Cost‑efficient early metabolite profiling
HµREL® Micro Livers:
- Long‑term incubation (up to 120 hours)
- Accurate modeling of CYP, UGT, AO, and FMO pathways
- Integrated clearance + metabolite ID workflows
- Proven correlation with in vivo clearance for low‑turnover drugs
HEPATOPAC® Micropatterned Co‑Culture:
- Weeks‑long metabolic competence
- Human‑relevant clearance estimates for challenging compounds
- Ideal for regulatory submissions and modelling applications
- Reliable prediction of very slow turnover compounds
Advanced Metabolite Identification & LC‑MS/MS Platforms
- High‑resolution MS for low‑abundance metabolites
- Structural elucidation + quantitative analysis
- Seamless integration with clearance assays for a full mechanistic picture
- Simultaneous QualQuant metabolite identification capabilities
Partner with Pharmaron
At Pharmaron, we provide complete end‑to‑end DMPK expertise, from early discovery through regulatory submission. Our global teams and state‑of‑the‑art platforms support confident decision‑making for low clearance compounds at every stage of development. If you require robust, predictive, and regulatory‑aligned in vitro low clearance data, we can help.
